Artificial intelligence in the prediction of protein-ligand interactions: recent advances and future directions

Brief Bioinform. 2022 Jan 17;23(1):bbab476. doi: 10.1093/bib/bbab476.

Abstract

New drug production, from target identification to marketing approval, takes over 12 years and can cost around $2.6 billion. Furthermore, the COVID-19 pandemic has unveiled the urgent need for more powerful computational methods for drug discovery. Here, we review the computational approaches to predicting protein-ligand interactions in the context of drug discovery, focusing on methods using artificial intelligence (AI). We begin with a brief introduction to proteins (targets), ligands (e.g. drugs) and their interactions for nonexperts. Next, we review databases that are commonly used in the domain of protein-ligand interactions. Finally, we survey and analyze the machine learning (ML) approaches implemented to predict protein-ligand binding sites, ligand-binding affinity and binding pose (conformation) including both classical ML algorithms and recent deep learning methods. After exploring the correlation between these three aspects of protein-ligand interaction, it has been proposed that they should be studied in unison. We anticipate that our review will aid exploration and development of more accurate ML-based prediction strategies for studying protein-ligand interactions.

Keywords: binding affinity; binding pose; binding site; deep learning; drug discovery; machine learning; protein–ligand interaction.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Antiviral Agents* / chemistry
  • Antiviral Agents* / pharmacokinetics
  • COVID-19 Drug Treatment*
  • COVID-19* / metabolism
  • Deep Learning*
  • Drug Discovery*
  • Humans
  • Ligands
  • Protein Interaction Maps*
  • SARS-CoV-2 / metabolism*

Substances

  • Antiviral Agents
  • Ligands